Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive OfficerGlobeNewsWire • 03/27/24
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy SymposiumGlobeNewsWire • 03/27/24
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 03/05/24
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific ConferenceGlobeNewsWire • 02/14/24
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesGlobeNewsWire • 01/11/24
Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/05/24
Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common StockGlobeNewsWire • 01/05/24
Dyne Therapeutics stock gains, Sarepta falls after muscular dystrophy trial resultsMarket Watch • 01/03/24
Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle DiseasesGlobeNewsWire • 01/03/24
Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER TrialsGlobeNewsWire • 01/02/24
Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical MilestonesGlobeNewsWire • 10/30/23
Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1GlobeNewsWire • 09/20/23